Neurocrine (NBIX) - Gross Profit Rate

NBIX (Neurocrine Biosciences Inc) - company brandmark

Neurocrine Biosciences (NBIX) specializes in neuromedicine innovations. Sales margins demonstrate operational returns, where 96.40 shows the current volume of the metric. The business relies on stringent patent protection amid fierce competition for breakthrough drugs. However, dependence on a single flagship product creates risks. High patient loyalty and FDA support ensure a stable revenue stream.

NBIX: Neurocrine Biosciences, Inc. Gross Margin 07/04/2022 - 11/20/2026

Analytical breakdowns and data insights for company neurocrine.com (NBIX)

- stock value and consensus price forecast:
- cash and cash flow statistics:
Signature product of Neurocrine Biosciences

Defensive assets are selected based on the resilience of cash flows to market volatility. Neurocrine Biosciences (NBIX) adheres to this principle due to stable demand for its drugs, despite the risks of raw material supply chain disruptions. Gross margin measures production efficiency by subtracting the cost of goods sold from revenue, as reflected in the value 96.40. Analyzing this gross profit percentage allows for an assessment of operating profitability and the risk of overpaying for the asset.

Direct competitors

Return on Gross Profit Biogen Corp|RGC (Regencell Corp) - Gross Margin|AXSM: Gross Profit Rate|Gross Profitability acadia-pharm.com (ACAD)|Gross Margin Xenon Pharmaceuticals (XENE)|Gross Profitability Viking Therapeutics VKTX|Gross Profit Rate SUPN|CPRX - Gross Profitability|Gross Profit Margin Denali Therapeutics|HRMY: Gross Margin|Biohaven - Gross Profit Rate|Return on Gross Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Return on Sales by Gross Profit|Return on Gross Profit PRAX (Praxis Medicines)|Anavex Corp - Gross Return on Sales|Gross Profitability CeriBell CBLL|Return on Sales by Gross Profit Prothena Biosciences (PRTA)|ALEC: Return on Gross Profit|ANNX - Gross Margin|Omeros Corp. (OMER) - Gross Profitability|Gross Profit Margin Neurogene Inc. (NGNE)|Return on Gross Profit ACIU|Gross Profitability VYGR|Gross Profitability Neumora (NMRA)|SCLX - Gross Profit Margin|Gross Margin TVGN (Tevogen Bio Holdings Inc.)|Gross Profit Rate ACOG|Cognition Therapeutics Inc. - Gross Margin|IKT - Gross Margin|SAVA: Gross Margin|Assertio Holdings, Inc. - Gross Profit Rate|COYA (Coya) - Gross Margin|Gross Return on Sales VTGN (Vistagen Therapeutics)|Gross Profitability Ovid Rx (OVID)|Acumen Pharmaceuticals - Gross Return on Sales|Gross Profitability CervoMed, Inc. CRVO|Gross Margin Alterity Therapeutics ATHE|CLNN: Return on Gross Profit|PEPG (pepgen.com) - Gross Return on Sales|Jupiter Neurosciences Inc (JUNS) - Gross Profitability|Relmada Therapeutics - Gross Profit Rate|ANVS (Annovis Bio Inc) - Gross Margin|GRCE: Gross Profit Rate|Gross Profitability Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Gross Profit Rate|Gross Profitability neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Gross Profit Margin|MTVA: Return on Gross Profit|NeurAxis, Inc (NRXS) - Return on Gross Profit|HSDT: Gross Margin|PASG - Return on Sales by Gross Profit|Gross Profitability Neuphoria Therapeutics, Inc.|Gross Profitability NERV|Gross Margin ATHA|ADXN (Addex Therapeutics Ltd) - Gross Profit Rate|Gross Profitability alzamend.com ALZN|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)